NIH-Funding

Reminder of Required Letter of Support for PAR-17-094 "Maximizing Investigators Research Award (R35)"

NIH Funding Announcements - Mon, 12/11/2017 - 11:53
Notice NOT-GM-18-011 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Studies in Neonatal and Pediatric Resuscitation (R01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/11/2017 - 11:36
Funding Opportunity PA-18-485 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Proposals can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.
Categories: NIH-Funding

Studies in Neonatal and Pediatric Resuscitation (R03 - Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/11/2017 - 11:36
Funding Opportunity PA-18-491 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Proposals can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.
Categories: NIH-Funding

Notice of Change in Eligibility for PAR-17-094 "Maximizing Investigators Research Award (R35)"

NIH Funding Announcements - Mon, 12/11/2017 - 11:35
Notice NOT-GM-18-012 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: SJ

WriteEdit-Grant Questions Blog - Mon, 12/11/2017 - 11:23

Hi, Applied to NIA on a R01 based on RFA mechanism and received a 13% percentile score. I sent to my PO two emails asking for chance of being funded with this score, one in Nov 29 and one in Dec 7, but still did not hear back from him. In our earlier communications, my PO indicated the NIA FY18 payline won’t be available until the end of Dec or early of January. What should I do to follow up? I don’t want to bother PO with too many emails. But really want to know whether we have chance to be funded with this score or whether we should prepare for resubmission. My PO did indicate that our proposal is 100% coded as AD research. Thanks a lot.

Categories: NIH-Funding

NIDCD Early Career Research(ECR) Award (R21 - Clinical Trials Optional)

NIH Funding Announcements - Mon, 12/11/2017 - 10:47
Funding Opportunity PAR-18-487 from the NIH Guide for Grants and Contracts. The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.
Categories: NIH-Funding

NIDCR Dental Specialty and PhD Program (DSPP)(K12-Clinical Trials Not Allowed)

NIH Funding Announcements - Mon, 12/11/2017 - 02:49
Funding Opportunity RFA-DE-18-012 from the NIH Guide for Grants and Contracts. The Dental Specialty and PhD Program (DSPP) FOA encourages applications for institutional research career development (K12) programs from organizations that propose to develop outstanding clinician scientists through an integrated program of advanced clinical training in a recognized dental specialty and supervised research training leading to a PhD in biomedical or behavioral science, or in another field applicable to dental, oral and craniofacial research. The program should accelerate the process of early career dentist scientists in achieving competencies in both clinical and research areas and facilitate the transition to an independent and productive research career dedicated to improving dental, oral and craniofacial health.
Categories: NIH-Funding

Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/11/2017 - 02:37
Funding Opportunity RFA-DK-17-035 from the NIH Guide for Grants and Contracts. NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing. Eventually, collections of iPSCs that capture the heterogeneity of T2D could be used to conduct "clinical trials in a dish", to discover biomarkers of response and to develop personalized treatments. An essential feature of this program will be a multidisciplinary approach that brings together basic science experts and physician scientists in stem cell biology, bioengineering, computational biology, pharmacology, liver biology, islet biology, adipose biology, metabolism and diabetes.
Categories: NIH-Funding

Academic Research Enhancement Award in Diseases within the Mission of NIDDK (R15 - Clinical Trial Required)

NIH Funding Announcements - Mon, 12/11/2017 - 02:14
Funding Opportunity PA-18-495 from the NIH Guide for Grants and Contracts. The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution. The purpose of this FOA is to support AREA grants for clinical trials focused on diseases within the mission of NIDDK.
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Sat, 12/09/2017 - 13:56

Yes – that means science will be as important as score (ie, IC will pick projects of most interest to them over a range of scores).

Categories: NIH-Funding

By: PI Phase 2 SBIR

WriteEdit-Grant Questions Blog - Fri, 12/08/2017 - 19:18

Thanks! The grant is under a specific announcement(RFA) with an earmarked funding. I am not sure whether this makes a difference.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Fri, 12/08/2017 - 18:30

Some R21 applications receive a percentile – I assume it depends on the FOA and review group (a certain number of R21 applications need to be reviewed each cycle to have a sufficient N for the percentile calculation).

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Fri, 12/08/2017 - 18:28

It will mostly depend on the comments in your summary statement and how high a priority your work is for the IC. Your PO probably won’t know much until next January or so (and even then might not be able to say much until later in the FY), but you can ask whether you should resubmit while you wait to see what happens with funding decisions.

Categories: NIH-Funding

By: Frank

WriteEdit-Grant Questions Blog - Fri, 12/08/2017 - 14:53

Does R21 still get a percentile? That is interesting. What is the impact score?

Categories: NIH-Funding

By: Frank

WriteEdit-Grant Questions Blog - Fri, 12/08/2017 - 14:52

Does R21 still get a percentile? That is interesting.

Categories: NIH-Funding

Notice of NICHD Participation in PAR-18-205 "NIBIB Biomedical Technology Resource Centers (P41 - Clinical Trial Optional)"

NIH Funding Announcements - Fri, 12/08/2017 - 13:59
Notice NOT-HD-17-030 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: PI Phase 2 SBIR

WriteEdit-Grant Questions Blog - Fri, 12/08/2017 - 13:40

I just received a score of 30 for a Phase 2 SBIR grant. The current guideline is 10-30 zone of consideration for FY18. I am still waiting to here from the PO how to interpret this. I am curious what is the likelihood of not getting funded if you are in the consideration zone, especially when you are in the the bubble like me. Thanks!

Categories: NIH-Funding